An interventional study of Myoinositol and D-Chiro-Inositol in Polycystic Ovarian Syndrome (PCOS), sponsored by Fauji Foundation Hospital. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Fauji Foundation Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Polycystic Ovary Syndrome with a site in Pakistan — 7 open to participants now, 10 under way, none of them phase 3. Polycystic Ovary Syndrome · Pakistan.
Among the 40 studies in Polycystic Ovary Syndrome with a site in Pakistan, this one is the 15th largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2024, is one of 28 with no phase, and was the 40th registered.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →7 of the 40 studies in Polycystic Ovary Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18–45 · Women only
Riphah International University · Sites in Pakistan
Ages 18–35 · Women only
Riphah International University · Sites in Pakistan
Ages 18–35 · Women only
Riphah International University · Sites in Pakistan
Ages 18–35 · Women only
Quaid-e-Azam Medical College · Sites in Pakistan
Ages 18–35 · Women only
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 3 · Phase 4 2
First in 2016; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 70 across the 39 interventional studies, 180 across the 1 observational. Of the 29 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 40 has an industry lead sponsor. The 10 most frequent:
Fauji Foundation Hospital is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Fauji Foundation Hospital has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Polycystic Ovary Syndrome with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07629895Quaid-e-Azam Medical CollegeMyo-Inositol Alone Versus Myo-Inositol Plus Alpha-Lactalbumin in Women With Polycystic Ovary Syndrome | 2027-04 |
| NCT07875400Riphah International UniversityHigh Intensity Interval Training Versus Mat Pilates in Women With PCOS | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Polycystic Ovary Syndrome with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polycystic ovary syndrome (PCOS) is a common hormonal disorder in women of reproductive age. It can cause irregular menstrual cycles and difficulty in achieving pregnancy due to anovulation (failure to release an egg from the ovary).
This randomized controlled trial will compare the outcome of combined Myo-inositol and D-chiro-inositol with Metformin among women with anovulatory PCOS.
A total of 90 women aged 18-40 years will be included. Participants will be randomly divided into two groups, with 45 women in each group.
Group A will receive Myo-inositol 2000 mg, D-chiro-inositol 50 mg, and folic acid 200 micrograms twice daily for three months. Group B will receive Metformin 500 mg twice daily for three months.
Both groups will receive dietary advice and instructions to walk and exercise for 30 minutes daily.
The primary outcome will be ovulation after treatment. Ovulation will be assessed by ultrasound examination. The study will compare the proportion of women achieving ovulation in both treatment groups.
The findings will help assess the comparative outcomes of these two treatment approaches in women with anovulatory PCOS.
Polycystic ovary syndrome (PCOS) is an endocrine disorder associated with menstrual irregularities, hyperandrogenism, insulin resistance, and anovulation. Anovulation can contribute to infertility and reproductive difficulties.
Myo-inositol and D-chiro-inositol are involved in insulin signalling and ovarian function. Their combined use may improve metabolic and reproductive features in women with PCOS. Metformin is an insulin-sensitizing medication commonly used in women with PCOS.
This study is designed to compare the outcome of combined Myo-inositol and D-chiro-inositol versus Metformin among women with anovulatory PCOS.
The study will be conducted at the Department of Obstetrics and Gynaecology, Fauji Foundation Hospital, Rawalpindi. It will be a randomized controlled trial using non-probability consecutive sampling. A total of 90 women aged 18-40 years will be enrolled and randomly allocated into two groups.
Group A will receive:
Group B will receive:
Both treatment regimens will continue for three months.
Women with known diabetes, hypertension, liver disease, renal disease, or a history of smoking will be excluded.
After treatment, ultrasound examination will be performed to assess follicular development. The study will assess ovulation according to the protocol's operational definition, which identifies a mature follicle measuring 17-22 mm on ultrasound.
The primary outcome will be the occurrence of ovulation. The proportion of women achieving this outcome will be compared between the two groups.
Data will be analyzed using SPSS version 26. Quantitative variables will be presented as mean and standard deviation. Qualitative variables will be presented as frequencies and percentages. The Chi-square test will be used to compare ovulation between the groups. A p-value of 0.05 or less will be considered statistically significant.
The findings will provide comparative evidence regarding these treatment approaches in women with anovulatory PCOS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive Myo-inositol 2000 mg, D-chiro-inositol 50 mg, and folic acid 200 micrograms twice daily for three months, along with dietary advice and instructions for 30 minutes of daily walking and exercise.
Dietary Supplement: Myoinositol · Dietary Supplement: D-Chiro-Inositol · Dietary Supplement: Folic Acid
Participants will receive Metformin 500 mg twice daily for three months, along with dietary advice and instructions for 30 minutes of daily walking and exercise.
Drug: MetFORMIN
Myo-inositol 2000 mg administered orally twice daily for 3 months, in combination with D-chiro-inositol 50 mg and folic acid 200 micrograms twice daily.
D-chiro-inositol 50 mg administered orally twice daily for 3 months, in combination with myo-inositol 2000 mg and folic acid 200 micrograms twice daily
Folic acid 200 micrograms administered orally twice daily for three months as part of the combination treatment with myo-inositol and D-chiro-inositol.
Metformin 500 mg administered orally twice daily for three months.
Proportion of Women Achieving Ovulation
Ovulation will be assessed by ultrasound examination after treatment. According to the study's operational definition, a mature ovarian follicle measuring 17-22 mm on ultrasound will be considered evidence of ovulation. The proportion of women achieving this outcome will be compared between the two treatment groups.
Time frame: At the end of three months of treatment
Plan to share: Undecided — currently not decided
Ran from Aug 2024 to primary completion in Aug 2026, 23 months.
Of 203 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's 23 months is above that.
Counting every sponsor, half of 218 studies reached it within 18 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chiro-inositol, (+)-
Fauji Foundation Hospital